We have developed an enhanced conditionally replicative canine oncolytic adenovirus, CAV2-AU-M3, armed with an anti-PD1 heavy chain antibody (HcAb), and evaluated its efficacy against osteosarcoma across four canine cell lines. The gene discussed is SLC3A2; the disease is osteosarcoma.